Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer

Trial Profile

Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2016

At a glance

  • Drugs IZN 6N4 (Primary)
  • Indications Stomatitis
  • Focus Therapeutic Use
  • Sponsors Izun Pharma
  • Most Recent Events

    • 17 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
    • 13 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Jan 2016 According to an Izun Pharmaceuticals media release, the results of this study will be presented at the Biotech Showcase, in January 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top